Hyperthyroidism: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(26 intermediate revisions by 7 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Hyperthyroidism}}
{{Hyperthyroidism}}
{{CMG}};{{AE}}{{AY}}
{{CMG}}; {{AE}}{{AY}}
 
'''<nowiki/>'<nowiki/>''For the WikiDoc patient information for this topic, click [[Hyperthyroidism (patient information)|here]]'''''
'''For the WikiDoc patient information for this topic, click [[Hyperthyroidism (patient information)|here]]''


==Overview==
==Overview==
[[Hormones|Thyroid hormones]] are responsible for regulating the [[basal metabolic rate]] of the body. Over secretion of thyroid hormones can lead to a wide variety of syndromes depending on the cause of the hyperthyroidism. Hyperthyroidism can be due to hyperactivity of the [[thyroid gland]] itself (primary hyperthyroidism) or due to abnormalities in the [[pituitary gland]] or the [[hypothalamus]] causing irregularities in the upper control of the gland. Hyperthyroidism can also be classified according to the results of iodine uptake study into high uptake, low uptake, and high or normal uptake. Hyperthyroidism must be differentiated from other diseases that can [[insomnia]], [[anxiety]] and [[hypertension]] such as [[pheochromocytoma]], [[generalized anxiety disorder]] and [[essential hypertension]]. The pathophysiology and the compilation of symptoms and signs differ between the different diseases causing hyperthyroid activity.
[[Hormones|Thyroid hormones]] are responsible for regulating the [[basal metabolic rate]] of the body. Over secretion of [[thyroid hormones]] can lead to a wide variety of [[syndromes]] depending on the cause of the hyperthyroidism. Hyperthyroidism can be due to hyperactivity of the [[thyroid gland]] itself (primary hyperthyroidism) or due to abnormalities in the [[pituitary gland]] or the [[hypothalamus]] causing irregularities in the upper control of the [[Thyroid|gland]]. Hyperthyroidism can also be classified according to the results of [[iodine]] uptake study into high uptake, high or normal uptake, and low uptake. Hyperthyroidism must be differentiated from other [[diseases]] that cause [[insomnia]], [[anxiety]], and [[hypertension]] such as [[pheochromocytoma]], [[generalized anxiety disorder]], and [[essential hypertension]]. The [[pathophysiology]] and the compilation of [[symptoms]] and [[signs]] differ between the different [[diseases]] causing high [[thyroid]] activity.


==Classification==
==Classification==


===According to the origin of the abnormality===
===According to the origin of the abnormality===
Hyperthyroidism is classified according to the origin of the lesion into primary, secondary and tertiary hyperthyroidism<ref name="pmid12679417">{{cite journal |vauthors=Monaco F |title=Classification of thyroid diseases: suggestions for a revision |journal=J. Clin. Endocrinol. Metab. |volume=88 |issue=4 |pages=1428–32 |year=2003 |pmid=12679417 |doi=10.1210/jc.2002-021260 |url=}}</ref>
Hyperthyroidism is classified according to the origin of the lesion into primary, secondary, and tertiary hyperthyroidism.<ref name="pmid12679417">{{cite journal |vauthors=Monaco F |title=Classification of thyroid diseases: suggestions for a revision |journal=J. Clin. Endocrinol. Metab. |volume=88 |issue=4 |pages=1428–32 |year=2003 |pmid=12679417 |doi=10.1210/jc.2002-021260 |url=}}</ref>


{{familytree/start}}
{{familytree/start}}
Line 17: Line 16:
{{familytree | | | | | | | | | |!| | | | | | | | }}
{{familytree | | | | | | | | | |!| | | | | | | | }}
{{familytree | | |,|-|-|-|-|-|-|+|-|-|-|-|-|-|.| }}
{{familytree | | |,|-|-|-|-|-|-|+|-|-|-|-|-|-|.| }}
{{familytree | | B01 | | | | | B02 | | | | | B03 |B01='''Primary hyperthytoidism'''|B02='''Secondary hyperthyroidism'''|B03='''Tertiary hyoperthyroidism'''|}}
{{familytree | | B01 | | | | | B02 | | | | | B03 |B01='''Primary hyperthyroidism'''|B02='''Secondary hyperthyroidism'''|B03='''Tertiary hyperthyroidism'''|}}
{{familytree | | |!| | | | | | |!| | | | | | |!| |}}
{{familytree | | |!| | | | | | |!| | | | | | |!| |}}
{{familytree | |boxstyle=text-align: left; | C01 | | | | | C02 | | | | | C03 | |C01=• [[Graves' disease|Grave’s disease]]<br>• [[Toxic thyroid nodule]]<br>• [[Thyroid adenoma]]<br>•  [[Multinodular goiter]]|C02=•  [[Pituitary adenoma]]<br>• [[Intracranial tumor|Intracranial tumors]] pressing [[pituitary gland]]|C03=• Excess thyroxin production due to disorders of the [[hypothalamus]]<br> which may be due to [[Intracranial tumor|intracranial tumors]] or [[Intracranial mass|masses]].}}  
{{familytree | |boxstyle=text-align: left; | C01 | | | | | C02 | | | | | C03 | |C01=• [[Graves' disease|Grave’s disease]]<br>• [[Toxic thyroid nodule]]<br>• [[Thyroid adenoma]]<br>•  [[Multinodular goiter]]|C02=•  [[Pituitary adenoma]]<br>• [[Intracranial tumor|Intracranial tumors]] pressing [[pituitary gland]]|C03=•   [[Intracranial tumor|Intracranial tumors]] or [[Intracranial mass|masses]] involving [[hypothalamus]]}}  
{{familytree/end}}
{{familytree/end}}


===According to iodine uptake===
===According to iodine uptake===
Hyperthyroidism can be classified according to the results of iodine uptake test into high uptake, high or normal uptake or low uptake.<ref name="urlThyroid disease classification - The Lancet">{{cite web |url=+http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(05)72981-0/abstract |title=Thyroid disease classification - The Lancet |format= |work= |accessdate=}}</ref>
[[Hyperthyroidism]] can be classified according to the results of [[iodine]] uptake test into high uptake, high or normal uptake, and low uptake.<ref name="urlThyroid disease classification - The Lancet">{{cite web |url=+http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(05)72981-0/abstract |title=Thyroid disease classification - The Lancet |format= |work= |accessdate=}}</ref>


{{familytree/start}}
{{familytree/start}}
{{familytree | | | | | | | | | A01 | | | | | |A01='''According to Iodine uptake'''}}
{{familytree | | | | | | | | | A01 | | | | | |A01='''According to iodine uptake'''}}
{{familytree | | | | | | | | | |!| | | | | | | | }}
{{familytree | | | | | | | | | |!| | | | | | | | }}
{{familytree | | |,|-|-|-|-|-|-|+|-|-|-|-|-|-|.| }}
{{familytree | | |,|-|-|-|-|-|-|+|-|-|-|-|-|-|.| }}
{{familytree | | B01 | | | | | B02 | | | | | B03 |B01='''High iodine uptake'''|B02='''High or normal uptake'''|B03='''Low uptake'''|}}
{{familytree | | B01 | | | | | B02 | | | | | B03 |B01='''High uptake'''|B02='''High or normal uptake'''|B03='''Low uptake'''|}}
{{familytree | | |!| | | | | | |!| | | | | | |!| |}}
{{familytree | | |!| | | | | | |!| | | | | | |!| |}}
{{familytree | |boxstyle=text-align: left; | C01 | | | | | C02 | | | | | C03 | |C01=• [[Graves' disease]]<br>• [[Toxic multinodular goiter]]<br>• [[Toxic thyroid adenoma]]<br>|C02=• Iodine caused hyperthyroidism<br>• [[Hashimoto's thyroiditis|Hashitoxicosis]]<br>• [[Germ cell tumors]] ([[choriocarcinoma]] in males and testicular germ cell tumors)<br>• [[Pituitary adenoma|Pituitary TSH producing adenoma]]|C03=• [[Subacute thyroiditis]]<br>• [[Hyperthyroidism]] due to ectopic thyroid tissue<br>• Factitious thyrotoxicosis<br>• [[Struma ovarii]]<br>• [[Thyroiditis|Painless thyroiditis]]<br>• [[Thyroiditis|Amiodarone induced thyroiditis-Type 1]]<br>• [[Thyroiditis|Amiodarone induced thyroiditis-Type 2]]}}  
{{familytree | |boxstyle=text-align: left; | C01 | | | | | C02 | | | | | C03 | |C01=• [[Graves' disease]]<br>• [[Toxic multinodular goiter]]<br>• [[Toxic thyroid adenoma]]<br>|C02=• Iodine caused hyperthyroidism<br>• [[Hashimoto's thyroiditis|Hashitoxicosis]]<br>• [[Germ cell tumors]] ([[choriocarcinoma]] in males and testicular germ cell tumors)<br>• [[Pituitary adenoma|Pituitary TSH producing adenoma]]|C03=• [[Subacute thyroiditis]]<br>• Hyperthyroidism due to ectopic [[thyroid]] tissue<br>• Factitious [[thyrotoxicosis]]<br>• [[Struma ovarii]]<br>• Painless [[thyroiditis]]<br>• Amiodarone induced [[thyroiditis]]-Type 1<br>• Amiodarone induced [[thyroiditis]]-Type 2}}  
{{familytree/end}}
{{familytree/end}}


==Differentiating hyperthyroidism from other diseases==
==Differentiating hyperthyroidism from other diseases==


Hyperthyroidism must be differentiated from other diseases that cause anxiety, elevated blood pressure and insomnia such as essential hypertension, generalized anxiety disorder, and pheochromocytoma.
Hyperthyroidism must be differentiated from other [[diseases]] that cause [[anxiety]], [[elevated blood pressure]], and [[insomnia]]; such as [[essential hypertension]], [[generalized anxiety disorder]], and [[pheochromocytoma]].


{| class="wikitable"
{| class="wikitable"
Line 58: Line 57:
|-
|-
| colspan="1" rowspan="1" style="background: #4479BA; padding: 5px 5px;" | {{fontcolor|#FFFFFF|Essential hypertension}}
| colspan="1" rowspan="1" style="background: #4479BA; padding: 5px 5px;" | {{fontcolor|#FFFFFF|Essential hypertension}}
|Most patients with hypertension are asymptomatic at the time of diagnosis. Common symptoms are listed below:
|Most patients with hypertension are asymptomatic at the time of diagnosis.  
Common symptoms are listed below:
*[[Headache]]
*[[Headache]]
*[[Blurry vision]]
*[[Blurry vision]]
Line 66: Line 66:
*[[Fatigue]]
*[[Fatigue]]
*[[Drowsiness]]
*[[Drowsiness]]
|JNC 7 recommends the following routine laboratory tests before initiation of therapy for hypertension''':'''
|The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7 express) recommends the following routine laboratory tests before initiation of therapy for hypertension:
*[[ECG|12-Lead electrocardiogram (ECG)]]
*[[ECG|12-Lead electrocardiogram (ECG)]]
*[[Urinalysis]], including urinary albumin excretion or albumin/creatinine ratio
*[[Urinalysis]], including urinary [[albumin]] excretion or [[albumin]]/[[creatinine]] ratio
*[[Blood glucose]]
*[[Blood glucose]]
*[[Hematocrit|Blood hematocrit]]
*[[Hematocrit|Blood hematocrit]]
Line 77: Line 77:
|-
|-
| colspan="1" rowspan="1" style="background: #4479BA; padding: 5px 5px;" | {{fontcolor|#FFFFFF|Generalized anxiety disorder}}
| colspan="1" rowspan="1" style="background: #4479BA; padding: 5px 5px;" | {{fontcolor|#FFFFFF|Generalized anxiety disorder}}
|According to '''DSM V''', the following criteria should be present to fit the diagnosis of [[generalized anxiety disorder]]:
|According to '''[[Diagnostic and statistical manual of mental disorders|DSM V]]''', the following criteria should be present to fit the [[diagnosis]] of [[generalized anxiety disorder]]:


#The presence of sense of apprehension or fear toward certain activities for most of the days for at least 6 months
#The presence of sense of apprehension or fear toward certain activities for most of the days for at least 6 months
#Difficulty to control the apprehension
#Difficulty to control the apprehension
#Associated restless, fatigue, irritability, difficulty concentration, muscle tension or sleep disturbance (only one of these manifestations)
#Associated restless, [[fatigue]], [[irritability]], difficulty [[concentration]], muscle [[tension]] or [[sleep disturbance]] (only one of these manifestations)
#The anxiety or the physical manifestations must affect the social and the daily life of the patient
#The [[anxiety]] or the physical manifestations must affect the social and the daily life of the patient
#Exclusion of another medical condition or the effect of another administered substance
#Exclusion of another medical condition or the effect of another administered substance
#Exclusion of another mental disorder causing the symptoms
#Exclusion of another mental disorder causing the symptoms
Line 91: Line 91:


*Vasomotor instability in the form of [[hot flush]]es, including [[sleep hyperhidrosis|night sweats]] and [[Sleep disorder|sleep disturbances]]
*Vasomotor instability in the form of [[hot flush]]es, including [[sleep hyperhidrosis|night sweats]] and [[Sleep disorder|sleep disturbances]]
*Urogenital atrophy causing [[Itch|itching]], dryness, [[bleeding]], watery discharge, [[Polyuria|urinary frequency]], [[urinary urgency]] and [[urinary incontinence]]
*Urogenital atrophy causing [[Itch|itching]], dryness, [[bleeding]], watery discharge, [[Polyuria|urinary frequency]], [[urinary urgency]], and [[urinary incontinence]]
*Skeletal symptoms in the form of [[osteoporosis]] (gradually developing over time), [[arthralgia|artharlgia]], [[myalgia|myalgia]] and [[back pain]]
*Skeletal symptoms in the form of [[osteoporosis]] (gradually developing over time), [[arthralgia|artharlgia]], [[myalgia|myalgia]], and [[back pain]]
*Psychological manifestations such as [[Mood disorder|mood disturbance]], [[irritability]], [[Fatigue (medical)|fatigue]], [[memory loss]] and [[Depression (mood)|depression]]
*Psychological manifestations such as [[Mood disorder|mood disturbance]], [[irritability]], [[Fatigue (medical)|fatigue]], [[memory loss]] and [[Depression (mood)|depression]]
*Sexual disorders: [[Libido|decreased libido]], [[Vaginal lubrication|vaginal dryness]], problems reaching orgasm and [[dyspareunia]]
*Sexual disorders: [[Libido|Decreased libido]], [[Vaginal lubrication|vaginal dryness]], problems reaching orgasm and [[dyspareunia]]
|
|
* [[Human chorionic gonadotropin|B-HCG]] should always be done first to rule out [[pregnancy]] especially in women under the age of 45 years
* [[Human chorionic gonadotropin|B-HCG]] should always be done first to rule out [[pregnancy]], especially in women under the age of 45 years.
* [[FSH]] can be measured but it can be falsely normal or low
* [[FSH]] can be measured but it can be falsely normal or low.
* [[TSH]], [[T3]] and [[T4]] to rule out thyroid abnormalities
* [[TSH]], [[T3]], and [[T4]] should be assessed to rule out [[thyroid]] abnormalities.
* [[Prolactin]] can be measured to rule out [[prolactinoma]] as a cause of [[menopause]]
* [[Prolactin]] can be measured to rule out [[prolactinoma]], as a cause of [[menopause]].
|-
|-
| colspan="1" rowspan="1" style="background: #4479BA; padding: 5px 5px;" | {{fontcolor|#FFFFFF|Opioid withdrawal disorder}}
| colspan="1" rowspan="1" style="background: #4479BA; padding: 5px 5px;" | {{fontcolor|#FFFFFF|Opioid withdrawal disorder}}
|According to '''DSM V''', the following criteria should be present to fit the diagnosis of opioid withdrawal:
|According to '''DSM V''', the following criteria should be present to fit the diagnosis of [[opioid withdrawal]]:
# Cessation of (or reduction in) [[Opioid use disorders|opioid use]] that has been heavy and prolonged (i.e., several weeks or longer) or administration of an [[opioid antagonist]] after a period of [[Opioid use disorders|opioid use]].
# Cessation of (or reduction in) [[Opioid use disorders|opioid use]] that has been heavy and prolonged (i.e., several weeks or longer) or administration of an [[opioid antagonist]] after a period of [[Opioid use disorders|opioid use]].
# Development of three or more of the following criteria minutes to days after cessation of drug use: [[Dysphoria|dysphoric mood]], [[nausea]] or [[vomiting]], [[muscle aches]], [[Lacrimation]] or [[rhinorrhea]], [[pupillary dilation]], [[piloerection]], or [[sweating]], [[diarrhea]], [[yawning]], [[fever]], and [[insomnia]].
# Development of three or more of the following criteria minutes to days after cessation of drug use: [[Dysphoria|Dysphoric mood]], [[nausea]] or [[vomiting]], [[muscle aches]], [[Lacrimation]] or [[rhinorrhea]], [[pupillary dilation]], [[piloerection]], or [[sweating]], [[diarrhea]], [[yawning]], [[fever]], and [[insomnia]].
# The signs or symptoms mentioned above must cause impairment of the daily functioning of the patient.
# The signs or symptoms mentioned above must cause impairment of the daily functioning of the patient.
#  The signs or symptoms mentioned above must not be attributed to other medical or mental disorders.
#  The signs or symptoms mentioned above must not be attributed to other medical or mental disorders.
|
|
* Urine drug screen to rule out any other associated drug abuse
* Urine drug screen to rule out any other associated [[drug abuse]]
* Routine blood work such as electrolytes and hemoglobin to rule out any associated disease explaining the symptoms  
* Routine blood work such as [[electrolytes]] and [[hemoglobin]] to rule out any associated [[disease]] explaining the symptoms  
|-
|-
| colspan="1" rowspan="1" style="background: #4479BA; padding: 5px 5px;" | {{fontcolor|#FFFFFF|Pheochromocytoma}}
| colspan="1" rowspan="1" style="background: #4479BA; padding: 5px 5px;" | {{fontcolor|#FFFFFF|Pheochromocytoma}}
|The hallmark symptoms of a [[pheochromocytoma]] are those of [[sympathetic nervous system]] hyperactivity, symptoms usually subside in less than one hour and they may include:
|The hallmark symptoms of a [[pheochromocytoma]] are those of [[sympathetic nervous system]] hyperactivity, symptoms usually subside in less than one hour and they may include:
*[[Palpitations]] especially in epinephrine producing tumors.
*[[Palpitations]], especially in epinephrine producing tumors
*[[Anxiety]] often resembling that of a [[panic attack]]
*[[Anxiety]] often resembling that of a [[panic attack]]
*[[Sweating]]
*[[Sweating]]
*[[Headaches]] occur in 90 % of patients.
*[[Headaches]] occur in 90 % of patients.
*Paroxysmal attacks of [[hypertension]] but some patients have normal blood pressure.
*Paroxysmal attacks of [[hypertension]], but some patients have normal blood pressure
*It may be asymptomatic and discovered by incidence screening especially [[MEN, type 2|MEN]] patients.
*It may be asymptomatic and discovered by incidence screening especially [[MEN, type 2|MEN]] patients
''Please note that not all patients with pheochromocytoma experience all classical symptoms''.
''Please note that not all patients with [[pheochromocytoma]] experience all classical symptoms''.
|Diagnostic lab findings associated with pheochromocytoma include:
|Diagnostic lab findings associated with pheochromocytoma include:
*Elevated plasma and urinary [[catecholamine]]s and [[metanephrine]]s
*Elevated plasma, urinary [[catecholamine]]s, and [[metanephrine]]s
*Elevated urinary [[vanillyl mandelic acid]]
*Elevated urinary [[vanillyl mandelic acid]]
|}
|}


===Differentiating the different causes of thyrotoxicosis===
===Differentiating the causes of thyrotoxicosis===
{| style="border: 0px; font-size: 90%; margin: 3px;" align="center"
{| style="border: 0px; font-size: 90%; margin: 3px;" align="center"
! colspan="1" rowspan="1" style="background: #4479BA; padding: 5px 5px;" | {{fontcolor|#FFFFFF|Cause of thyrotoxicosis}}
! colspan="1" rowspan="1" style="background: #4479BA; padding: 5px 5px;" | {{fontcolor|#FFFFFF|Cause of thyrotoxicosis}}
! colspan="1" rowspan="1" style="background: #4479BA; padding: 5px 5px;" | {{fontcolor|#FFFFFF|TSH receptor Antibodies}}
! colspan="1" rowspan="1" style="background: #4479BA; padding: 5px 5px;" | {{fontcolor|#FFFFFF|TSH receptor antibodies}}
! colspan="1" rowspan="1" style="background: #4479BA; padding: 5px 5px;" | {{fontcolor|#FFFFFF|Thyroid US}}
! colspan="1" rowspan="1" style="background: #4479BA; padding: 5px 5px;" | {{fontcolor|#FFFFFF|Thyroid US}}
! colspan="1" rowspan="1" style="background: #4479BA; padding: 5px 5px;" | {{fontcolor|#FFFFFF|Color flow Doppler}}
! colspan="1" rowspan="1" style="background: #4479BA; padding: 5px 5px;" | {{fontcolor|#FFFFFF|Color flow Doppler}}
Line 202: Line 202:
| style="padding: 5px 5px; background: #F5F5F5;" | Reduced/absent flow
| style="padding: 5px 5px; background: #F5F5F5;" | Reduced/absent flow
| style="padding: 5px 5px; background: #F5F5F5;" | ↓
| style="padding: 5px 5px; background: #F5F5F5;" | ↓
| style="padding: 5px 5px; background: #F5F5F5;" | ↓ serum thyroglobulin
| style="padding: 5px 5px; background: #F5F5F5;" | ↓ Serum thyroglobulin
|-
|-
| colspan="1" rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Struma ovarii}}
| colspan="1" rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Struma ovarii}}
Line 225: Line 225:
|-
|-
| style="padding: 5px 5px; background: #4479BA;" | {{fontcolor|#FFFFFF|Drugs that interfere with the immune system}}
| style="padding: 5px 5px; background: #4479BA;" | {{fontcolor|#FFFFFF|Drugs that interfere with the immune system}}
| style="padding: 5px 5px; background: #F5F5F5;" | [[Interferon alfa-2a clinical pharmacology|Interferon-alfa]] is a well-known cause of thyroid abnormality. It mostly leads to the development of de novo antithyroid [[antibodies]].<ref name="pmid8351956">{{cite journal |vauthors=Vialettes B, Guillerand MA, Viens P, Stoppa AM, Baume D, Sauvan R, Pasquier J, San Marco M, Olive D, Maraninchi D |title=Incidence rate and risk factors for thyroid dysfunction during recombinant interleukin-2 therapy in advanced malignancies |journal=Acta Endocrinol. |volume=129 |issue=1 |pages=31–8 |year=1993 |pmid=8351956 |doi= |url=}}</ref>
| style="padding: 5px 5px; background: #F5F5F5;" | [[Interferon alfa-2a clinical pharmacology|Interferon-alfa]] is a well-known cause of [[thyroid]] abnormality. It mostly leads to the development of de novo [[antithyroid]] [[antibodies]].<ref name="pmid8351956">{{cite journal |vauthors=Vialettes B, Guillerand MA, Viens P, Stoppa AM, Baume D, Sauvan R, Pasquier J, San Marco M, Olive D, Maraninchi D |title=Incidence rate and risk factors for thyroid dysfunction during recombinant interleukin-2 therapy in advanced malignancies |journal=Acta Endocrinol. |volume=129 |issue=1 |pages=31–8 |year=1993 |pmid=8351956 |doi= |url=}}</ref>
|-
|-
| style="padding: 5px 5px; background: #4479BA;" | {{fontcolor|#FFFFFF|Lithium}}
| style="padding: 5px 5px; background: #4479BA;" | {{fontcolor|#FFFFFF|Lithium}}
Line 231: Line 231:
|-
|-
| style="padding: 5px 5px; background: #4479BA;" | {{fontcolor|#FFFFFF|Palpation thyroiditis}}
| style="padding: 5px 5px; background: #4479BA;" | {{fontcolor|#FFFFFF|Palpation thyroiditis}}
| style="padding: 5px 5px; background: #F5F5F5;" | Manipulation of the thyroid gland during thyroid [[biopsy]] or neck surgery and vigorous palpation during the physical examination may cause transient [[hyperthyroidism]].
| style="padding: 5px 5px; background: #F5F5F5;" | Manipulation of the [[thyroid gland]] during [[thyroid]] [[biopsy]] or neck [[surgery]] and vigorous palpation during the physical examination may cause transient hyperthyroidism.
|-
|-
| colspan="1" rowspan="4" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Exogenous and ectopic hyperthyroidism }}
| colspan="1" rowspan="4" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Exogenous and ectopic hyperthyroidism }}
| style="padding: 5px 5px; background: #4479BA;" | {{fontcolor|#FFFFFF|Factitious ingestion of thyroid hormone}}
| style="padding: 5px 5px; background: #4479BA;" | {{fontcolor|#FFFFFF|Factitious ingestion of thyroid hormone}}
| style="padding: 5px 5px; background: #F5F5F5;" |The diagnosis is based on the clinical features, laboratory findings, and 24-hour radioiodine uptake.<ref name="pmid2666114">{{cite journal |vauthors=Cohen JH, Ingbar SH, Braverman LE |title=Thyrotoxicosis due to ingestion of excess thyroid hormone |journal=Endocr. Rev. |volume=10 |issue=2 |pages=113–24 |year=1989 |pmid=2666114 |doi=10.1210/edrv-10-2-113 |url=}}</ref>
| style="padding: 5px 5px; background: #F5F5F5;" |The diagnosis is based on the clinical features, laboratory findings, and 24-hour [[radioiodine]] uptake.<ref name="pmid2666114">{{cite journal |vauthors=Cohen JH, Ingbar SH, Braverman LE |title=Thyrotoxicosis due to ingestion of excess thyroid hormone |journal=Endocr. Rev. |volume=10 |issue=2 |pages=113–24 |year=1989 |pmid=2666114 |doi=10.1210/edrv-10-2-113 |url=}}</ref>
|-
|-
| style="padding: 5px 5px; background: #4479BA;" | {{fontcolor|#FFFFFF|Acute hyperthyroidism from a levothyroxine overdose}}
| style="padding: 5px 5px; background: #4479BA;" | {{fontcolor|#FFFFFF|Acute hyperthyroidism from a levothyroxine overdose}}
| style="padding: 5px 5px; background: #F5F5F5;" |The diagnosis is based on the clinical features, laboratory findings, and 24-hour radioiodine uptake.<ref name="pmid23067331">{{cite journal |vauthors=Jha S, Waghdhare S, Reddi R, Bhattacharya P |title=Thyroid storm due to inappropriate administration of a compounded thyroid hormone preparation successfully treated with plasmapheresis |journal=Thyroid |volume=22 |issue=12 |pages=1283–6 |year=2012 |pmid=23067331 |doi=10.1089/thy.2011.0353 |url=}}</ref>
| style="padding: 5px 5px; background: #F5F5F5;" |The diagnosis is based on the clinical features, laboratory findings, and 24-hour [[radioiodine]] uptake.<ref name="pmid23067331">{{cite journal |vauthors=Jha S, Waghdhare S, Reddi R, Bhattacharya P |title=Thyroid storm due to inappropriate administration of a compounded thyroid hormone preparation successfully treated with plasmapheresis |journal=Thyroid |volume=22 |issue=12 |pages=1283–6 |year=2012 |pmid=23067331 |doi=10.1089/thy.2011.0353 |url=}}</ref>
|-
|-
| style="padding: 5px 5px; background: #4479BA;" | {{fontcolor|#FFFFFF|Struma ovarii}}
| style="padding: 5px 5px; background: #4479BA;" | {{fontcolor|#FFFFFF|Struma ovarii}}
| style="padding: 5px 5px; background: #F5F5F5;" |Functioning thyroid tissue is present in an [[ovarian neoplasm]].
| style="padding: 5px 5px; background: #F5F5F5;" |Functioning [[thyroid]] tissue is present in an [[ovarian neoplasm]].
|-
|-
| style="padding: 5px 5px; background: #4479BA;" | {{fontcolor|#FFFFFF|Functional thyroid cancer metastases}}
| style="padding: 5px 5px; background: #4479BA;" | {{fontcolor|#FFFFFF|Functional thyroid cancer metastases}}
Line 247: Line 247:
|-
|-
| colspan="2" rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Hashitoxicosis }}
| colspan="2" rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Hashitoxicosis }}
| style="padding: 5px 5px; background: #F5F5F5;" |It is an autoimmune thyroid disease that initially presents with hyperthyroidism and a high radioiodine uptake caused by TSH-receptor antibodies similar to Graves' disease. It is then followed by the development of hypothyroidism due to the infiltration of the thyroid gland with [[Lymphocyte|lymphocytes]] and the resultant autoimmune-mediated destruction of thyroid tissue, similar to chronic lymphocytic thyroiditis.<ref name="pmid5171000">{{cite journal |vauthors=Fatourechi V, McConahey WM, Woolner LB |title=Hyperthyroidism associated with histologic Hashimoto's thyroiditis |journal=Mayo Clin. Proc. |volume=46 |issue=10 |pages=682–9 |year=1971 |pmid=5171000 |doi= |url=}}</ref>
| style="padding: 5px 5px; background: #F5F5F5;" |It is an autoimmune thyroid disease that initially presents with hyperthyroidism and a high [[radioiodine]] uptake caused by [[TSH receptor|TSH-receptor]] antibodies similar to [[Graves' disease]]. It is then followed by the development of [[hypothyroidism]] due to the infiltration of the [[thyroid gland]] with [[Lymphocyte|lymphocytes]] and the resultant autoimmune-mediated destruction of [[thyroid]] tissue, similar to chronic [[lymphocytic thyroiditis]].<ref name="pmid5171000">{{cite journal |vauthors=Fatourechi V, McConahey WM, Woolner LB |title=Hyperthyroidism associated with histologic Hashimoto's thyroiditis |journal=Mayo Clin. Proc. |volume=46 |issue=10 |pages=682–9 |year=1971 |pmid=5171000 |doi= |url=}}</ref>
|-  
|-  
| colspan="2" rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Toxic adenoma and toxic multinodular goiter}}
| colspan="2" rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Toxic adenoma and toxic multinodular goiter}}
| style="padding: 5px 5px; background: #F5F5F5;" |Toxic adenoma and [[toxic multinodular goiter]] are results of focal/diffuse [[hyperplasia]] of thyroid follicular cells independent of TSH regulation. Findings of single or multiple [[nodules]] are seen on physical examination or thyroid scan.<ref name="pmid2040867">{{cite journal |vauthors=Laurberg P, Pedersen KM, Vestergaard H, Sigurdsson G |title=High incidence of multinodular toxic goitre in the elderly population in a low iodine intake area vs. high incidence of Graves' disease in the young in a high iodine intake area: comparative surveys of thyrotoxicosis epidemiology in East-Jutland Denmark and Iceland |journal=J. Intern. Med. |volume=229 |issue=5 |pages=415–20 |year=1991 |pmid=2040867 |doi= |url=}}</ref>
| style="padding: 5px 5px; background: #F5F5F5;" |Toxic adenoma and [[toxic multinodular goiter]] are results of focal/diffuse [[hyperplasia]] of [[thyroid]] follicular cells independent of [[TSH]] regulation. Findings of single or multiple [[nodules]] are seen on physical examination or [[thyroid]] scan.<ref name="pmid2040867">{{cite journal |vauthors=Laurberg P, Pedersen KM, Vestergaard H, Sigurdsson G |title=High incidence of multinodular toxic goitre in the elderly population in a low iodine intake area vs. high incidence of Graves' disease in the young in a high iodine intake area: comparative surveys of thyrotoxicosis epidemiology in East-Jutland Denmark and Iceland |journal=J. Intern. Med. |volume=229 |issue=5 |pages=415–20 |year=1991 |pmid=2040867 |doi= |url=}}</ref>
|-
|-
| colspan="2" rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Iodine-induced hyperthyroidism  }}
| colspan="2" rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Iodine-induced hyperthyroidism  }}
| style="padding: 5px 5px; background: #F5F5F5;" |It is uncommon but can develop after an iodine load, such as administration of contrast agents used for angiography or computed tomography (CT), or iodine-rich drugs such as [[amiodarone]].
| style="padding: 5px 5px; background: #F5F5F5;" |It is uncommon but can develop after an [[iodine]] load, such as administration of contrast agents used for [[angiography]] or [[Computed tomography|computed tomography (CT)]], or [[iodine]]-rich drugs such as [[amiodarone]].
|-
|-
| colspan="2" rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Trophoblastic disease and germ cell tumors }}
| colspan="2" rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Trophoblastic disease and germ cell tumors }}
| style="padding: 5px 5px; background: #F5F5F5;" |[[Thyroid-stimulating hormone]] and [[HCG]] have a common alpha-subunit and a beta-subunit with considerable homology. As a result, [[HCG]] has weak thyroid-stimulating activity and high titer HCG may mimic hyperthyroidism.<ref name="pmid19605510">{{cite journal |vauthors=Oosting SF, de Haas EC, Links TP, de Bruin D, Sluiter WJ, de Jong IJ, Hoekstra HJ, Sleijfer DT, Gietema JA |title=Prevalence of paraneoplastic hyperthyroidism in patients with metastatic non-seminomatous germ-cell tumors |journal=Ann. Oncol. |volume=21 |issue=1 |pages=104–8 |year=2010 |pmid=19605510 |doi=10.1093/annonc/mdp265 |url=}}</ref>
| style="padding: 5px 5px; background: #F5F5F5;" |[[Thyroid-stimulating hormone]] and [[HCG]] have a common alpha-subunit and a beta-subunit with considerable homology. As a result, [[HCG]] has weak thyroid-stimulating activity and high [[titer]] [[HCG]] may mimic hyperthyroidism.<ref name="pmid19605510">{{cite journal |vauthors=Oosting SF, de Haas EC, Links TP, de Bruin D, Sluiter WJ, de Jong IJ, Hoekstra HJ, Sleijfer DT, Gietema JA |title=Prevalence of paraneoplastic hyperthyroidism in patients with metastatic non-seminomatous germ-cell tumors |journal=Ann. Oncol. |volume=21 |issue=1 |pages=104–8 |year=2010 |pmid=19605510 |doi=10.1093/annonc/mdp265 |url=}}</ref>
|}
|}


Line 265: Line 265:
|}
|}


* [[Thyroid hormone|Thyroid hormones (T3 and T4)]] are regulating [[basal metabolic rate]], influence oxygen consumption by tissues. They are crucial for normal development of the brain and growth of the body, especially in prepubertal period.<ref name="pmid11949270">{{cite journal |vauthors=Kirsten D |title=The thyroid gland: physiology and pathophysiology |journal=Neonatal Netw |volume=19 |issue=8 |pages=11–26 |year=2000 |pmid=11949270 |doi=10.1891/0730-0832.19.8.11 |url=}}</ref>
* [[Thyroid hormone|Thyroid hormones (T3 and T4)]] are regulating [[basal metabolic rate]], influence [[oxygen]] consumption by tissues. They are crucial for normal development of the [[brain]] and growth of the body, especially in prepubertal period.<ref name="pmid11949270">{{cite journal |vauthors=Kirsten D |title=The thyroid gland: physiology and pathophysiology |journal=Neonatal Netw |volume=19 |issue=8 |pages=11–26 |year=2000 |pmid=11949270 |doi=10.1891/0730-0832.19.8.11 |url=}}</ref>
* Secretion of thyroid hormones follows upper control from the [[hypothalamus]] and the [[pituitary]]. [[Thyrotropin-releasing hormone|Thyroid releasing hormone (TRH)]] acts on thyrotropes releasing cells in the pituitary causing them to release [[Thyroid-stimulating hormone|thyroid stimulating hormone (TSH)]].  
* Secretion of [[thyroid hormones]] follows upper control from the [[hypothalamus]] and the [[pituitary]]. [[Thyrotropin-releasing hormone|Thyroid releasing hormone (TRH)]] acts on [[thyrotropes]] releasing cells in the [[pituitary]] causing them to release [[Thyroid-stimulating hormone|thyroid stimulating hormone (TSH)]].  
* [[TSH]] acts on [[thyroid gland]] by binding to specific membrane receptors and activating an intracellular pathway involving [[cAMP]] that ends in the formation and secretion of thyroid hormones.
* [[TSH]] acts on [[thyroid gland]] by binding to specific membrane receptors and activating an [[intracellular]] pathway involving [[cAMP]] that ends in the formation and secretion of [[thyroid hormones]].
* [[Iodine]] is essential for the synthesis of thyroid hormones. The daily iodide need is about 100mcg / day. Iodide is uptaken through a special Na/I transporter found in the membrane of thyroid follicular cell. After the iodide uptake, it goes through a series of organic reactions ending in the formation of the two forms of thyroid hormones: [[T3]] and [[T4]]. [[T3]] and [[T4]] remain stored in the thyroglobulin of the follicles and are released in response to further stimulation by [[TSH]] to the [[Thyroid follicle|thyroid follicles]].
* [[Iodine]] is essential for the synthesis of [[thyroid hormones]]. The daily [[iodide]] need is about 100 mcg/day. [[Iodide]] is up taken through a special Na/I transporter found in the membrane of [[thyroid]] follicular cell. After the [[iodide]] uptake, it goes through a series of organic reactions ending in the formation of the two forms of [[thyroid hormones]]: [[T3]] and [[T4]]. [[T3]] and [[T4]] remain stored in the [[thyroglobulin]] of the follicles and are released in response to further stimulation by [[TSH]] to the [[Thyroid follicle|thyroid follicles]].
* While [[T3]] is 3 to 5 times more potent than [[T4]], it represents only one-fourth of the total hormone secretion. [[T3]] is thought to be the biologically active form of the of the two forms of the hormone. Most of the circulating [[T3]] is due to peripheral conversion of [[T4]] in the liver and peripheral tissues while only a small percentage is secreted directly from the [[thyroid gland]] itself.
* While [[T3]] is 3 to 5 times more potent than [[T4]], it represents only one-fourth of the total hormone secretion. [[T3]] is thought to be the biologically active form of the of the two forms of the hormone. Most of the circulating [[T3]] is due to peripheral conversion of [[T4]] in the liver and peripheral tissues while only a small percentage is secreted directly from the [[thyroid gland]] itself.
* [[T3]] and [[T4]] act on nuclear receptors (DNA binding proteins) and cause the regulate the transcription of many proteins to regulate the [[metabolic rate]] of the body.
* [[T3]] and [[T4]] act on nuclear receptors ([[DNA]] binding [[proteins]]) and cause the regulate the [[transcription]] of many [[proteins]] to regulate the [[metabolic rate]] of the body.
* The higher regulation of [[thyroxin]] secretion follows the negative feedback role, meaning that high levels of [[T3]] and [[T4]] will suppress [[TRH]] and [[TSH]] secretion and vice versa (Low levels of [[Thyroxin|thyroxine]] will stimulate [[TRH]] and [[TSH]] secretion). This is useful in diagnosing the cause of hyperthyroidism (in secondary hyperthyroidism where the [[pituitary]] or the [[hypothalamus]] are the sources of the disease. [[TSH]] will be high, while in primary hyperthyroidism where the gland is the source of the excess hormones, [[TSH]] will be low).
* The higher regulation of [[thyroxine]] secretion follows the [[negative feedback]] role, meaning that high levels of [[T3]] and [[T4]] will suppress [[TRH]] and [[TSH]] secretion and vice versa (Low levels of [[Thyroxin|thyroxine]] will stimulate [[TRH]] and [[TSH]] secretion). This is useful in diagnosing the cause of hyperthyroidism (in secondary hyperthyroidism, where the [[pituitary]] or the [[hypothalamus]] are the sources of the disease, [[TSH]] will be high; while in primary hyperthyroidism where the gland is the source of the excess hormones, [[TSH]] will be low).
* In [[graves' disease]], the most common cause of hyperthyroidism. The disorder lies in the secretion of [[Thyroid-stimulating hormone|thyroid stimulating antibodies (TSI)]] that work on [[Thyroid follicular cell|thyroid follicular]] cells causing an excessive uncontrolled release of the [[Thyroxin|thyroxine]]. [[Thyroid-stimulating hormone|TSI]] responsible for many other aspects of the disease such as ophthalmopathy and the skin manifestations. This is thought to be due to the [[Epitope|epitopic]] similarity between [[antigens]] on the surface of these cells and the thyroid receptors.<ref name="pmid14262190">{{cite journal |vauthors=ADAMS DD |title=PATHOGENESIS OF THE HYPERTHYROIDISM OF GRAVES'S DISEASE |journal=Br Med J |volume=1 |issue=5441 |pages=1015–9 |year=1965 |pmid=14262190 |pmc=2166943 |doi= |url=}}</ref>
*[[Graves' disease]] which is the most common cause of hyperthyroidism lies in the secretion of [[Thyroid-stimulating hormone|thyroid stimulating antibodies (TSI)]] that work on [[Thyroid follicular cell|thyroid follicular]] cells causing an excessive uncontrolled release of the [[Thyroxin|thyroxine]]. [[Thyroid-stimulating hormone|TSI]] responsible for many other aspects of the disease such as ophthalmopathy and the skin manifestations. This is thought to be due to the [[Epitope|epitopic]] similarity between [[antigens]] on the surface of these cells and the thyroid receptors.<ref name="pmid14262190">{{cite journal |vauthors=ADAMS DD |title=PATHOGENESIS OF THE HYPERTHYROIDISM OF GRAVES'S DISEASE |journal=Br Med J |volume=1 |issue=5441 |pages=1015–9 |year=1965 |pmid=14262190 |pmc=2166943 |doi= |url=}}</ref>
* [[Toxic nodular goiter]] involves the growth of a various number of [[nodules]] (ranging from one to tens). These nodules either bleed and undergo degeneration and [[fibrosis]] followed by [[calcification]] or they might have autonomous activity producing excess [[thyroxin]].
* [[Toxic nodular goiter]] involves the growth of a various number of [[nodules]] (ranging from one to tens). These nodules either bleed and undergo degeneration and [[fibrosis]] followed by [[calcification]] or they might have autonomous activity producing excess [[thyroxin]].
* The majority of circulating [[T3]] and [[T4]] are bound to plasma proteins and thus not active ([[T4]] is mostly bound to [[Thyroxine binding globulins|thyroxine binding globulin]] and [[T3]] is mostly bound to [[transthyretin]]). Conditions that impair the production of thyroid binding globulins (such as pregnancy, [[liver failure]], and certain drug administration) cause a change in the total serum thyroxine but the free [[T3]] and [[T4]] remain normal and the patient remains euthyroid (this carries only laboratory significance).<ref name="pmid6134495">{{cite journal |vauthors=Chopra IJ, Solomon DH |title=Pathogenesis of hyperthyroidism |journal=Annu. Rev. Med. |volume=34 |issue= |pages=267–81 |year=1983 |pmid=6134495 |doi=10.1146/annurev.me.34.020183.001411 |url=}}</ref>
* The majority of circulating [[T3]] and [[T4]] are bound to [[plasma proteins]] and thus not active ([[T4]] is mostly bound to [[Thyroxine binding globulins|thyroxine binding globulin]] and [[T3]] is mostly bound to [[transthyretin]]). Conditions that impair the production of thyroid binding [[globulins]] (such as [[pregnancy]], [[liver failure]], and certain drug administration) cause a change in the total serum [[thyroxine]] but the free [[T3]] and [[T4]] remain normal and the patient remain (this carries only laboratory significance).<ref name="pmid6134495">{{cite journal |vauthors=Chopra IJ, Solomon DH |title=Pathogenesis of hyperthyroidism |journal=Annu. Rev. Med. |volume=34 |issue= |pages=267–81 |year=1983 |pmid=6134495 |doi=10.1146/annurev.me.34.020183.001411 |url=}}</ref>


==References==
==References==
{{reflist|2}}
{{reflist|2}}

Latest revision as of 16:05, 7 July 2020

Hyperthyroidism Microchapters

Patient Information

Overview

Classification

Differentiating hyperthyroidism from other diseases

Pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Younes M.B.B.CH [2] 'For the WikiDoc patient information for this topic, click here

Overview

Thyroid hormones are responsible for regulating the basal metabolic rate of the body. Over secretion of thyroid hormones can lead to a wide variety of syndromes depending on the cause of the hyperthyroidism. Hyperthyroidism can be due to hyperactivity of the thyroid gland itself (primary hyperthyroidism) or due to abnormalities in the pituitary gland or the hypothalamus causing irregularities in the upper control of the gland. Hyperthyroidism can also be classified according to the results of iodine uptake study into high uptake, high or normal uptake, and low uptake. Hyperthyroidism must be differentiated from other diseases that cause insomnia, anxiety, and hypertension such as pheochromocytoma, generalized anxiety disorder, and essential hypertension. The pathophysiology and the compilation of symptoms and signs differ between the different diseases causing high thyroid activity.

Classification

According to the origin of the abnormality

Hyperthyroidism is classified according to the origin of the lesion into primary, secondary, and tertiary hyperthyroidism.[1]

 
 
 
 
 
 
 
 
According to the origin of the abnormality
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Primary hyperthyroidism
 
 
 
 
Secondary hyperthyroidism
 
 
 
 
Tertiary hyperthyroidism
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Grave’s disease
Toxic thyroid nodule
Thyroid adenoma
Multinodular goiter
 
 
 
 
Pituitary adenoma
Intracranial tumors pressing pituitary gland
 
 
 
 
Intracranial tumors or masses involving hypothalamus
 

According to iodine uptake

Hyperthyroidism can be classified according to the results of iodine uptake test into high uptake, high or normal uptake, and low uptake.[2]

 
 
 
 
 
 
 
 
According to iodine uptake
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
High uptake
 
 
 
 
High or normal uptake
 
 
 
 
Low uptake
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Graves' disease
Toxic multinodular goiter
Toxic thyroid adenoma
 
 
 
 
• Iodine caused hyperthyroidism
Hashitoxicosis
Germ cell tumors (choriocarcinoma in males and testicular germ cell tumors)
Pituitary TSH producing adenoma
 
 
 
 
Subacute thyroiditis
• Hyperthyroidism due to ectopic thyroid tissue
• Factitious thyrotoxicosis
Struma ovarii
• Painless thyroiditis
• Amiodarone induced thyroiditis-Type 1
• Amiodarone induced thyroiditis-Type 2
 

Differentiating hyperthyroidism from other diseases

Hyperthyroidism must be differentiated from other diseases that cause anxiety, elevated blood pressure, and insomnia; such as essential hypertension, generalized anxiety disorder, and pheochromocytoma.

Disease Prominent clinical features Investigations
Hyperthyroidism The main symptoms include:
Essential hypertension Most patients with hypertension are asymptomatic at the time of diagnosis.

Common symptoms are listed below:

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7 express) recommends the following routine laboratory tests before initiation of therapy for hypertension:
Generalized anxiety disorder According to DSM V, the following criteria should be present to fit the diagnosis of generalized anxiety disorder:
  1. The presence of sense of apprehension or fear toward certain activities for most of the days for at least 6 months
  2. Difficulty to control the apprehension
  3. Associated restless, fatigue, irritability, difficulty concentration, muscle tension or sleep disturbance (only one of these manifestations)
  4. The anxiety or the physical manifestations must affect the social and the daily life of the patient
  5. Exclusion of another medical condition or the effect of another administered substance
  6. Exclusion of another mental disorder causing the symptoms
-
Menopause The perimenopausal symptoms are caused by an overall drop, as well as dramatic but erratic fluctuations, in the levels of estrogens, progestin, and testosterone. Some of these symptoms such as formication etc may be associated with the hormone withdrawal process.
  • B-HCG should always be done first to rule out pregnancy, especially in women under the age of 45 years.
  • FSH can be measured but it can be falsely normal or low.
  • TSH, T3, and T4 should be assessed to rule out thyroid abnormalities.
  • Prolactin can be measured to rule out prolactinoma, as a cause of menopause.
Opioid withdrawal disorder According to DSM V, the following criteria should be present to fit the diagnosis of opioid withdrawal:
  1. Cessation of (or reduction in) opioid use that has been heavy and prolonged (i.e., several weeks or longer) or administration of an opioid antagonist after a period of opioid use.
  2. Development of three or more of the following criteria minutes to days after cessation of drug use: Dysphoric mood, nausea or vomiting, muscle aches, Lacrimation or rhinorrhea, pupillary dilation, piloerection, or sweating, diarrhea, yawning, fever, and insomnia.
  3. The signs or symptoms mentioned above must cause impairment of the daily functioning of the patient.
  4. The signs or symptoms mentioned above must not be attributed to other medical or mental disorders.
Pheochromocytoma The hallmark symptoms of a pheochromocytoma are those of sympathetic nervous system hyperactivity, symptoms usually subside in less than one hour and they may include:
  • Palpitations, especially in epinephrine producing tumors
  • Anxiety often resembling that of a panic attack
  • Sweating
  • Headaches occur in 90 % of patients.
  • Paroxysmal attacks of hypertension, but some patients have normal blood pressure
  • It may be asymptomatic and discovered by incidence screening especially MEN patients

Please note that not all patients with pheochromocytoma experience all classical symptoms.

Diagnostic lab findings associated with pheochromocytoma include:

Differentiating the causes of thyrotoxicosis

Cause of thyrotoxicosis TSH receptor antibodies Thyroid US Color flow Doppler Radioactive iodine uptake/Scan Other features
Graves' disease + Hypoechoic pattern Ophthalmopathy, dermopathy, acropachy
Toxic nodular goiter - Multiple nodules - Hot nodules at thyroid scan -
Toxic adenoma - Single nodule - Hot nodule -
Subacute thyroiditis - Heterogeneous hypoechoic areas Reduced/absent flow Neck pain, fever, and
elevated inflammatory index
Painless thyroiditis - Hypoechoic pattern Reduced/absent flow -
Amiodarone induced thyroiditis-Type 1 - Diffuse or nodular goiter ↓/Normal/↑ ↓ but higher than in Type 2 High urinary iodine
Amiodarone induced thyroiditis-Type 2 - Normal Absent ↓/absent High urinary iodine
Central hyperthyroidism - Diffuse or nodular goiter Normal/↑ Inappropriately normal or high TSH
Trophoblastic disease - Diffuse or nodular goiter Normal/↑ -
Factitious thyrotoxicosis - Variable Reduced/absent flow ↓ Serum thyroglobulin
Struma ovarii - Variable Reduced/absent flow Abdominal RAIU

Prominent features in the different causes of hyperthyroidism

Disease Findings
Thyroiditis Direct chemical toxicity with inflammation Amiodarone, sunitinib, pazopanib, axitinib, and other tyrosine kinase inhibitors may also be associated with a destructive thyroiditis.[3][4]
Radiation thyroiditis Patients treated with radioiodine may develop thyroid pain and tenderness 5 to 10 days later, due to radiation-induced injury and necrosis of thyroid follicular cells and associated inflammation.
Drugs that interfere with the immune system Interferon-alfa is a well-known cause of thyroid abnormality. It mostly leads to the development of de novo antithyroid antibodies.[5]
Lithium Patients treated with lithium are at a high risk of developing painless thyroiditis and Graves' disease.
Palpation thyroiditis Manipulation of the thyroid gland during thyroid biopsy or neck surgery and vigorous palpation during the physical examination may cause transient hyperthyroidism.
Exogenous and ectopic hyperthyroidism Factitious ingestion of thyroid hormone The diagnosis is based on the clinical features, laboratory findings, and 24-hour radioiodine uptake.[6]
Acute hyperthyroidism from a levothyroxine overdose The diagnosis is based on the clinical features, laboratory findings, and 24-hour radioiodine uptake.[7]
Struma ovarii Functioning thyroid tissue is present in an ovarian neoplasm.
Functional thyroid cancer metastases Large bony metastases from widely metastatic follicular thyroid cancer cause symptomatic hyperthyroidism.
Hashitoxicosis It is an autoimmune thyroid disease that initially presents with hyperthyroidism and a high radioiodine uptake caused by TSH-receptor antibodies similar to Graves' disease. It is then followed by the development of hypothyroidism due to the infiltration of the thyroid gland with lymphocytes and the resultant autoimmune-mediated destruction of thyroid tissue, similar to chronic lymphocytic thyroiditis.[8]
Toxic adenoma and toxic multinodular goiter Toxic adenoma and toxic multinodular goiter are results of focal/diffuse hyperplasia of thyroid follicular cells independent of TSH regulation. Findings of single or multiple nodules are seen on physical examination or thyroid scan.[9]
Iodine-induced hyperthyroidism It is uncommon but can develop after an iodine load, such as administration of contrast agents used for angiography or computed tomography (CT), or iodine-rich drugs such as amiodarone.
Trophoblastic disease and germ cell tumors Thyroid-stimulating hormone and HCG have a common alpha-subunit and a beta-subunit with considerable homology. As a result, HCG has weak thyroid-stimulating activity and high titer HCG may mimic hyperthyroidism.[10]

Pathophysiology

Rgulation of thyroxin secretion - By CFCF; slightly modified by Geo-Science-International - This file was derived from Thyroid vector.svg:, CC BY-SA 3.0, https://commons.wikimedia.org/w/index.php?curid=47043638

References

  1. Monaco F (2003). "Classification of thyroid diseases: suggestions for a revision". J. Clin. Endocrinol. Metab. 88 (4): 1428–32. doi:10.1210/jc.2002-021260. PMID 12679417.
  2. [+http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(05)72981-0/abstract "Thyroid disease classification - The Lancet"] Check |url= value (help).
  3. Lambert M, Unger J, De Nayer P, Brohet C, Gangji D (1990). "Amiodarone-induced thyrotoxicosis suggestive of thyroid damage". J. Endocrinol. Invest. 13 (6): 527–30. PMID 2258582.
  4. Ahmadieh H, Salti I (2013). "Tyrosine kinase inhibitors induced thyroid dysfunction: a review of its incidence, pathophysiology, clinical relevance, and treatment". Biomed Res Int. 2013: 725410. doi:10.1155/2013/725410. PMC 3824811. PMID 24282820.
  5. Vialettes B, Guillerand MA, Viens P, Stoppa AM, Baume D, Sauvan R, Pasquier J, San Marco M, Olive D, Maraninchi D (1993). "Incidence rate and risk factors for thyroid dysfunction during recombinant interleukin-2 therapy in advanced malignancies". Acta Endocrinol. 129 (1): 31–8. PMID 8351956.
  6. Cohen JH, Ingbar SH, Braverman LE (1989). "Thyrotoxicosis due to ingestion of excess thyroid hormone". Endocr. Rev. 10 (2): 113–24. doi:10.1210/edrv-10-2-113. PMID 2666114.
  7. Jha S, Waghdhare S, Reddi R, Bhattacharya P (2012). "Thyroid storm due to inappropriate administration of a compounded thyroid hormone preparation successfully treated with plasmapheresis". Thyroid. 22 (12): 1283–6. doi:10.1089/thy.2011.0353. PMID 23067331.
  8. Fatourechi V, McConahey WM, Woolner LB (1971). "Hyperthyroidism associated with histologic Hashimoto's thyroiditis". Mayo Clin. Proc. 46 (10): 682–9. PMID 5171000.
  9. Laurberg P, Pedersen KM, Vestergaard H, Sigurdsson G (1991). "High incidence of multinodular toxic goitre in the elderly population in a low iodine intake area vs. high incidence of Graves' disease in the young in a high iodine intake area: comparative surveys of thyrotoxicosis epidemiology in East-Jutland Denmark and Iceland". J. Intern. Med. 229 (5): 415–20. PMID 2040867.
  10. Oosting SF, de Haas EC, Links TP, de Bruin D, Sluiter WJ, de Jong IJ, Hoekstra HJ, Sleijfer DT, Gietema JA (2010). "Prevalence of paraneoplastic hyperthyroidism in patients with metastatic non-seminomatous germ-cell tumors". Ann. Oncol. 21 (1): 104–8. doi:10.1093/annonc/mdp265. PMID 19605510.
  11. Kirsten D (2000). "The thyroid gland: physiology and pathophysiology". Neonatal Netw. 19 (8): 11–26. doi:10.1891/0730-0832.19.8.11. PMID 11949270.
  12. ADAMS DD (1965). "PATHOGENESIS OF THE HYPERTHYROIDISM OF GRAVES'S DISEASE". Br Med J. 1 (5441): 1015–9. PMC 2166943. PMID 14262190.
  13. Chopra IJ, Solomon DH (1983). "Pathogenesis of hyperthyroidism". Annu. Rev. Med. 34: 267–81. doi:10.1146/annurev.me.34.020183.001411. PMID 6134495.